Skip to main content

Table 1 Comparison of demographic and clinical characteristics of cases ( E. faecium ) and controls

From: Algorithm for pre-emptive glycopeptide treatment in patients with haematologic malignancies and an Enterococcus faecium bloodstream infection

Demographics

Cases (n = 33)

Controls (n = 66)

p-value

Male gender

18 (68.2%)

45 (54.5%)

0.184

Age, mean ± SD, years

58.0 ± 11.3

52.2 ± 9.1

0.008

Type of malignancy: a

  

0.378

   Leukaemia (AML, MDS, ALL) for chemotherapy

19 (57.6%)

28 (42.6%)

 

   Leukemia for allogeneic stem cell transplantation

2 (6.1%)

2 (3.0%)

 

   Lymphoma’s, Kahler, CLL and others undergoing autologous stem cell transplantation

6 (18.2%)

17 (25.8%)

 

   Lympfhoma’s, Kahler, CLL not undergoing autologous stem cell transplantation

6 (18.2%)

19 (28.8%)

 

Status of disease:

   

   Remission

9 (27.3%)

11 (16.7%)

0.215

   Not in remission b

24 (72.7%)

55 (83.3%)

0.215

   Relapse

7 (21.2%)

14 (21.2%)

1.000

Reason for admission:

  

0.476

   Infection

4 (12.1%)

13 (19.7%)

 

   Chemotherapy

21(63.6%)

34 (51.5%)

 

   Stem cell transplantation c

8 (24.2%)

19 (28.8%)

 

Length of hospital stay:

   

   Length in days prior to positive blood culture, median (range)

21 (2–52)

13.5 (1–84)

0.007

   Length in days 1 year before admission, median (range)

43 (6–131)

24 (1–133)

0.018

Signs of organ failure: d

   

   Renal (creatinine > 176 μmol/L)

2 (6.1%)

3 (4.5%)

0.746

   Hepatic (bilirubin >34 mmol/L)

2 (6.1%)

0 (0.0%)

0.109

   Lung (bilateral lung infiltrates)

4 (12.1%)

10 (15.2%)

0.769

Days of fever, median (range) d

2 (0–7)

0 (0–6)

0.001

Neutropenia:

   

   Neutropenia <0.1 × 109/L e

20 (60.6%)

19 (28.8%)

0.002

   Neutropenia <0.5 × 109/L e

28 (84.8%)

28 (42.4%)

<0.001

   Neutropenia <2.0 × 109/L e

29 (87.9%)

39 (59.1%)

0.004

   Duration of neutropenia <0.5 × 109/L prior to blood culture, median (range)

8.0 (0–27)

0.0 (0–26)

<0.001

CRP (C-reactive protein in mg/L):

   

   Levels 7 days prior to blood culture, median (range)

26 (3–263)

47 (5–347)

0.07

   Levels at time of blood culture, median (range)

188 (7–288)

108 (3–426)

0.006

   At time of blood culture CRP >125 mg/L

23 (69.7%)

24 (36.4%)

0.002

Antibiotic therapy at time of blood culture and/or 30 days before:

   

   Penicillins

24 (72.7%)

40 (60.6%)

0.234

   Cotrimoxazole

12 (36.4%)

18 (27.3%)

0.353

   Quinolones

25 (75.8%)

51 (77.3%)

0.866

   Cephalosporins

6 (18.2%)

4 (6.1%)

0.079

   Carbapenems

6 (18.2%)

5 (7.6%)

0.113

   Others f

19 (57.6%)

16 (24.2%)

0.001

  1. aAML  acute myeloid leukaemia, MDS  myelodysplastic syndrome, ALL  acute lymphoblastic leukaemia, CLL  chronic lymphoblastic leukaemia. bIncluding patients partially in remission. cAllogeneic as well as autologous stem cell transplantation. dAt the day of blood culture till 7 days prior to blood culture. eAt the day of blood culture withdrawal fcolistin, tetracyclin, macrolides, aminoglycosides, metronidazole.
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us